According to recent reports, the Trump administration’s efforts to improve government efficiency, overseen by the Department of Government Efficiency (DOGE), are causing unexpected disruptions, particularly in the health and medical technology sector. The process for acquiring government approval for life-saving tools has slowed, and the repercussions for public health could be significant.
The Department of Government Efficiency (DOGE) implemented substantial workforce reductions that affected a large number of federal employees. Many of those laid off were probationary employees, which is standard practice during an employee’s first year of service. A significant number of these employees held AI-related roles, a fact that has sent shockwaves through the medical technology sector.
AI’s rapid development in recent years has made these roles crucial for the future of medical technology. The Biden administration launched an ‘AI talent surge’ to bring experts into the executive branch. Many of those roles have been eliminated, creating a sudden shortage of AI expertise in the federal government.
This shift is especially felt in the healthcare industry where recent AI developments have transformed the way we approach patient care. Companies are working to create AI-powered devices for monitoring heart health. These tools are essential for combating cardiovascular disease, a condition for which an estimated 80% of cases are preventable.
These monitoring tools need FDA approval before they can be used. However, the FDA has been forced to fire many of its AI experts who conduct the approval process. This loss of talent could significantly extend approval times, potentially by months or even years.
Fortunately, the government is attempting to reverse some of the layoffs. However, it remains unclear how many of the affected workers will return. To attract and retain top AI talent, the government needs to offer job security, an important component of federal employment that is now in question.
FDA clearance is more than just a procedural step; it is a necessity. The FDA’s rigorous testing ensures the safety of new medical devices. My company has seen this firsthand, having obtained FDA approval last year for a portable 12-lead AI-powered ECG device. Its effectiveness has been proven, thanks to the FDA process.
Moreover, FDA approval promotes innovation. Prolonged approval backlogs may discourage companies from developing new technologies. This slowdown has serious implications for rural areas, which already face limited access to healthcare. Over 80% of these counties are medically underserved, making remote patient monitoring (RPM) devices invaluable. The National Association of Counties has reported on these “healthcare deserts.”
RPM devices can also help to reduce the strain on hospitals, which are struggling with overcrowding. Remote monitoring can help diagnose problems, connect patients with providers remotely, and even schedule in-person appointments. This is the future of medical care.
The medical device sector is a global, growing industry, projected to increase from $542 billion in 2024 to $887 billion by 2032, according to Fortune Business Insights. If the U.S. approval system remains slow, other countries may gain significant market share.
Ultimately, the government must restore AI expertise to the FDA to strengthen both the health of the workforce and the advancement of medical technology. This will enable Americans to lead healthier and, by extension, more efficient lives.
The opinions expressed in Fortune.com commentary pieces are solely the views of their authors and do not necessarily reflect the opinions and beliefs of Fortune.
